Resources

Real-time (RT) continuous glucose monitoring (CGM) can significantly improve daytime and nighttime glucose control, but only if patients use it properly and get the right support, according to a psychologist who studies barriers to successful implementation of the technology…. 

Conversion from exenatide to liraglutide is well tolerated and provides additional glycemic control and cardiometabolic benefits….

In patients with Type 2 diabetes, inhaled insulin before each meal, plus insulin glargine before bedtime, is just as effective at controlling blood sugar as conventional twice-daily premixed biaspart insulin therapy, according to new research…. 

Obese boys who engaged in regular aerobic or resistance exercise — without dietary changes — had significant improvements over 3 months in their total body fat, visceral adipose tissue concentrations, and insulin sensitivity than their more sluggish counterparts, according to the results of a randomized study….

In patients with Type 1 diabetes and poor glycemic control, the use of a sensor-augmented insulin pump significantly improved their A1c levels, compared with a regimen of multiple daily insulin injections, according to a new study…. 

From heart transplant material to cancer therapies, pigs have provided a host of opportunities for humans, Now pigs have come to the rescue once again — this time for diabetes….

Some patients with diabetes may not benefit from aggressive management of cardiovascular risk factors and some may even be harmed, according to a statistical model based on a government health survey.… 

One of the important announcements coming out of the American Diabetes Association’s 70th Scientific Sessions were the results of a little known NIH study titled, “The Healthy Study: Interventions to reduce early diabetes risk.” This may be a new model of how we can prevent our children from getting diabetes….

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset Type 1 diabetes….

A new first in class drug getting close to approval to treat Type 2 diabetes showed the potential to help lower blood glucose levels through a different mechanism than current treatments, according to new studies….